Biopharma | Boston, Mass.

Scorpion Therapeutics Closes $108 Million Series A for Precision Small Molecule Oncology

Scorpion Therapeutics, a next-generation precision oncology company, closed a $108 million Series A round, led by Atlas Venture, Omega Funds, and Vida Ventures, with Abingworth and Partners HealthCare Innovation participating. Funds will be used to advance Precision Oncology 2.0., the next wave in precision medicine, with safe and tolerated small molecule drugs providing better outcomes to many more cancer patients. [Full story]